Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Liabilities and Shareholders Equity (2016 - 2025)

Sunshine Biopharma's Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $30.1 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 1.57% year-over-year to $30.1 million; the TTM value through Dec 2025 reached $122.7 million, up 0.74%, while the annual FY2025 figure was $30.1 million, 1.57% down from the prior year.
  • Liabilities and Shareholders Equity reached $30.1 million in Q4 2025 per SBFM's latest filing, down from $31.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $42.0 million in Q2 2022 to a low of $1.8 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $24.4 million, with a median of $29.2 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 2818.08% in 2021, then tumbled 32.34% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.2 million in 2021, then skyrocketed by 1227.52% to $29.2 million in 2022, then dropped by 6.49% to $27.3 million in 2023, then rose by 11.75% to $30.6 million in 2024, then dropped by 1.57% to $30.1 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Liabilities and Shareholders Equity are $30.1 million (Q4 2025), $31.5 million (Q3 2025), and $32.0 million (Q2 2025).